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Abstract
Targeted nanoparticles are increasingly being engineered for the treatment of cancer. By design,
they can passively accumulate in tumors, selectively bind to targets in their environment, and
deliver localized treatments. However, the penetration of targeted nanoparticles deep into tissue
can be hindered by their slow diffusion and a high binding affinity. As a result, they often localize
to areas around the vessels from which they extravasate, never reaching the deep-seeded tumor
cells, thereby limiting their efficacy. To increase tissue penetration and cellular accumulation, we
propose generalizable guidelines for nanoparticle design and validate them using two different
computer models that capture the potency, motion, binding kinetics, and cellular internalization of
targeted nanoparticles in a section of tumor tissue. One strategy that emerged from the models was
delaying nanoparticle binding until after the nanoparticles have had time to diffuse deep into the
tissue. Results show that nanoparticles that are designed according to these guidelines do not
require fine-tuning of their kinetics or size and can be administered in lower doses than classical
targeted nanoparticles for a desired tissue penetration in a large variety of tumor scenarios. In the
future, similar models could serve as a testbed to explore engineered tissue-distributions that arise
when large numbers of nanoparticles interact in a tumor environment.
© 2014 Published by Elsevier Ltd. All rights reserved.
Corresponding Author: Sangeeta Bhatia, Massachusetts Institute of Technology, 77 Massachusetts Ave. Bldg. 76-453, Cambridge,
MA 02139, USA, sbhatia@mit.edu, +1 617 324 0610.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Nano Today. Author manuscript; available in PMC 2014 July 07.
Published in final edited form as:
Nano Today. 2013 December 1; 8(6): 566–576. doi:10.1016/j.nantod.2013.11.001.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
Targeting; Nanoparticle; Modeling; Tissue Penetration; Cancer; Systems Nanotechnology
1. Introduction
Nanoparticles targeted to surface receptors that are over-expressed in certain tumors have
the potential to improve specificity and intracellular delivery of therapeutic payloads to
cancer cells [1]. Their size, typically in the 5–200 nm range, enables them to leak out of
angiogenic vessels and accumulate in tumors [2]. Once in the tumor tissue, nanoparticles
must traverse the interstitial space to reach all cells that require treatment [3]. This is a
challenging goal because high, uniform pressure in tumor environments causes nanoparticle
motion to be mostly diffusive [4, 5]. In addition, nanoparticles with large binding affinities,
amplified by multivalent interactions, will accumulate in the first cells they encounter after
extravasation as depicted in Fig. 1A. The resulting binding-site barriers, previously
demonstrated with antibodies [6] and recently with targeted nanoparticles [7, 8], prevent
treatments from reaching cells far away from vessels.
Efforts have been made to overcome transport barriers that limit the accumulation of
nanoparticles in tumor tissue [4]. Solutions include increasing nanoparticle circulation time
[9], or activating transvascular transport, and parenchyma penetration through the use of
tumor-penetrating peptides [10, 11].1 Rather than approach nanoparticle design empirically,
models by Thurber et al. [6, 12] and Wittrup et al. [13] are able to quantitatively predict the
impact of dosage, blood flow, extravasation, diffusion, and binding kinetics on the
distribution of antibodies and macromolecules in tumors. Other models by Ferrari et al. [14]
focus on the targeting of nanoparticles to the vasculature. To date, most models have been
used to investigate how existing nanoparticle designs impact tissue distribution; the next
step is to implement computational models that drive innovation by helping to explore novel
nanoparticle designs and offer the potential to yield generalizable guidelines for a variety of
tumor scenarios. Furthermore, current models do not consider the ability of targeted
nanoparticles to accumulate at effective doses in individual cancer cells given a specific
therapeutic cargo. Finally, researchers typically rely on deterministic models that assume
nanoparticles can be modeled as populations that are not subject to stochastic variations.
Using a deterministic model, which is further validated by stochastic simulations, we
systematically explore nanoparticle designs that result in binding-site barriers and propose
generalizable guidelines to avoid such barriers without increasing the injected dose or fine-
tuning nanoparticle diffusion coefficients and binding kinetics. Rather than consider all
transport parameters that impact nanoparticle distribution, we model a challenging
representative tumor scenario in which a defined low number of targeted nanoparticles must
accumulate to kill individual receptor-rich cells, including those located furthest from the
tumor vasculature. Results show that many targeted nanoparticle designs reported in the
literature lead to superficial tumor penetration in this scenario. The therapeutic payload is
1See our video on nanoparticle transport in tumors: http://youtu.be/gBYkYzj7CKM
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taken into account in calculating the number of nanoparticles needed to affect tumor cells.
Optimization of the deterministic model shows that overcoming the barrier would typically
require large treatment doses to saturate cells near tumor vessels before nanoparticles can
penetrate deeper into the tissue. Rather than fine-tune the size and binding affinity of
nanoparticles to improve tissue penetration, we augment our models to explore novel design
guidelines that rely on delaying nanoparticle binding until after the nanoparticles have had
time to diffuse deep into the tissue. Results in simulation show that nanoparticles designed
following these guidelines can accumulate at effective levels in all cells that require
treatment with the use of smaller injected doses than would be necessary for conventional
targeted nanoparticles. The design guidelines are immediately generalizable to a variety of
tumor scenarios that account for variations in surface receptor expression and recycling,
drug encapsulation, number of nanoparticles, and the rate at which nanoparticles accumulate
in the tumor tissue. Furthermore, we outline existing, established technologies that could be
used to implement these guidelines in reality. Beyond deep tissue penetration, we aim to
ultimately control the distribution of nanoparticles in tissue with sufficient precision to
accommodate heterogeneous treatment and imaging needs. To this end, we propose the use
of nanoparticles with targeting moieties whose unveiling is a function of an environmental
stimulus rather than time or external triggers. Using this strategy, we demonstrate in
simulation that the nanoparticles could achieve inverted internalization gradients by
accumulating more in cells further away from the vasculature. Such a distribution pattern
could be useful to deliver drugs deep into tumors.
2. Materials and methods
2.1 In Silico Models
Computer simulations can help engineer nanotreatments by rapidly predicting experimental
outcomes for a large set of design parameters. To this end, we formulate both deterministic
and stochastic reaction-diffusion models to simulate the transport, binding kinetics, and
internalization of nanoparticles in a section of tumor tissue.
The main challenge is to back out usable guidelines that generalize across tumor scenarios
and can therefore be implemented in reality. Varying all the parameters that impact
nanoparticle transport is unrealistic and typically results in a variety of regimes and tradeoffs
that are difficult to translate to actionable guidelines. Instead, we focus on a representative
scenario, which embodies a challenging tumor environment that would realistically be
encountered by targeted nanoparticles. Solutions to this scenario have the potential to
automatically generalize to many tumor environments. Our focus is on scenarios that result
in binding-site barriers. Specifically, we consider the situation depicted in Fig. 1B in which
nanoparticles leaving a vessel near the central, poorly perfused area of the tumor need to
penetrate deep into the tumor tissue up to a depth L, while accumulating at levels sufficient
to kill each of the N cells along the way. Each cell is represented as a cubic region that has a
volume of S3, where S is the largest cell dimension. The percent injected dose (PID) of
drugs with high potency P reaching the tumor section is sufficient to theoretically kill or
treat (e.g. through siRNA delivery) all cells if distributed uniformly throughout the tissue.
The PID is measured at a predefined time T after the nanoparticle injection. Based on the
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weight W of a mouse and the ratio of the entire tumor volume VT to the volume of the
simulated tumor section S2 L, we can approximate the minimal injected dose (ID) of drugs
in mass per body weight needed to accumulate at PID levels at time T after injection. Each
nanoparticle encapsulates a large number E of drug molecules with molar mass M, resulting
in a low number NP0 of nanoparticles that are present in the simulated tumor section for the
predefined injected dose of drug. To approximate a slow clearance of the nanoparticles from
the blood, the model is initialized with NP0 nanoparticles that enter the first cell region of
the tumor tissue section at a uniform rate over the duration of the circulation time TC.
Nanoparticles diffuse through the tumor tissue and bind to highly expressed receptors [15]
that are immediately recycled upon internalization of the nanoparticles. We can approximate
NP0 as
Eq. 1
where NA is the Avogadro constant.
The reaction-diffusion model illustrated in Fig. 1C describes the formation and dissociation
of nanoparticle-receptor complexes and the internalization of nanoparticles in each cell of
the tumor model [16]. The species in the reaction network are defined as NPF, free
nanoparticles; NPI, internalized nanoparticles; R, receptors; and C, nanoparticle-receptor
complexes. Free nanoparticles diffuse between cell regions with diffusion coefficient D. The
reaction network is:
Eq. 2
where ka and kd are the association and dissociation rate constants and ki is the
internalization rate constant.
Both the stochastic and deterministic models proposed here describe the population
dynamics of nanoparticles in tumors, and thus are less computationally expensive than
simulations of the movement of individual nanoparticles and their interactions with other
nanoparticles or receptors. The stochastic model has a more legitimate physical basis than
the deterministic model: it captures fluctuations and correlations in population levels that
occur in reaction-diffusion systems, and it realistically represents these populations as
integers that change by discrete amounts [13]. The deterministic formulation is accurate for
systems with large populations whose fluctuations remain small relative to the absolute
population levels. This model represents the system state as concentration fields that evolve
continuously according to partial differential equations. The dimensionality of the
deterministic model is independent of the population levels, and for large populations it is
faster to numerically solve this model than to simulate the stochastic model. Hence, when
accurate, the deterministic model is more suitable as a tool for quickly predicting the system
behavior for a large set of parameters. In this paper, we use deterministic models to simulate
all experiments and validate key results using a stochastic simulator.
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2.2 Deterministic Model
The deterministic model of the system consists of a set of reaction-diffusion partial
differential equations (PDEs) that govern the expected spatiotemporal evolution of the
different species populations in the one-dimensional domain of interest. The population
levels of free nanoparticles, NPF(x,t), internalized nanoparticles, NPI(x,t), receptors, R(x,t),
and nanoparticle-receptor complexes, C(x,t), are defined at each position x ∈ [0 L] at each
time t ≥ 0 and are expressed in units [number/cell]. The equations for the PDE model are:
NP0 represents a direct measure of the number of nanoparticles present in the simulated
tumor section after extravasation and clearance at time T. Focus is on modeling where these
nanoparticles distribute within the simulated tumor tissue. Initially, no nanoparticles are
present in the domain, and NR receptors are distributed uniformly throughout each of the
cells. The model boundary condition at x = 0 is defined as a constant-rate extravasation of
the NP0 free nanoparticles into the first cell region over time period TC. Due to the local
symmetry of the tumor environment at the micro-scale, we assume that nanoparticles that
diffuse out of the tumor section at x = L are replaced by nanoparticles flowing in from
adjacent tissue. Hence, a Neumann boundary condition is applied at x = L:
The deterministic model is numerically integrated in MATLAB (Mathworks) using a finite
difference method with 20 or more uniformly spaced nodes.
2.3 Stochastic Model
The stochastic model of the system takes the form of a Reaction-Diffusion (or Multivariate)
Master Equation [17, 18]. In this model, the spatial domain is discretized into cubic
subvolumes that are chosen small enough to be approximated as well-mixed regions [19].
The populations of different species in each subvolume change when chemical reactions
occur inside the subvolume or when nanoparticles diffuse into or out of the subvolume. A
stochastic simulation algorithm can be used to compute numerical realizations of the species
populations over time in a way that takes into account the fact that these populations are
integer-valued and exhibit randomness in their time evolution [20]. Various spatial
stochastic simulators for reaction-diffusion systems have been developed in recent years
[21]. We implement a stochastic simulator that is based on the freely available Stochastic
Simulator Compiler (SSC) [22]2. Briefly, for each cell region, the simulator determines how
probable a reaction is compared to other reactions and when the next reaction should occur.
2Stochastic Simulator Compiler: http://web.mit.edu/irc/ssc/.
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Based on the reaction network described in Eq. 2, associations happen with probability ka ·
NPF · R per unit time, dissociations with probability kd · C per unit time, and internalizations
with probability ki · C per unit time. Diffusion is modeled as a reaction in which a free
nanoparticle jumps between neighboring cell regions with rate constant D/S2; this
occurrence happens with probability 2 NPF · D/S2 per unit time. The next reaction should
therefore happen after an exponentially distributed random time with mean 1/(ka · NPF · R +
kd · C + ki · C + 2 NPF · D/S2) seconds and should randomly be chosen proportionally to the
probability rate at which each reaction happens. After each reaction, the species populations
and reaction probability rates are updated.
3. Results
3.1 Binding-Site Barriers
Providing guidelines for the improvement of nanoparticle design requires an understanding
of which design parameters result in binding-site barriers. We focus on exploring parameters
that have a direct effect on the distribution of nanoparticles in tissue after extravasation and
can be modified through engineering. For example, diffusion coefficients can be modified
by changing the size of nanoparticles [23, 24] or by relaxing the extracellular matrix [4],
while binding kinetics can be modified by acting on multivalency and engineering targeting
ligands [25]. Toward this end, we identified a relevant range of nanoparticle radii r and
dissociation constants, defined as KD = kd/ka, from the literature (Table 1).
Diffusion coefficients D were determined using the Stokes-Einstein equation [33] based on
nanoparticle radii ranging from 2 nm to 500 nm and viscosities ranging from values for
water to values for tumor tissue (10-fold increase in viscosity [4]). We simulated the effect
of combinations of D and KD in a representative challenging tumor scenario in which
liposomes carrying high loads of a cytotoxic drug doxorubicin (e.g. Doxil) are targeted to
over-expressed receptors [34] such as folate on KB cells [25] or HER-2 in certain breast
cancer lines [35]. The values of the parameters for the scenario are given in Table 2.
Particles are required to penetrate at least L = 200 μm into the tissue [4], targeting 20 cells
along the way. Only 1% of the injected dose reaches the tumor, which is typically the lower
bound in tumor tissue accumulation for targeted nanoparticles [13, 36–38]. The PID is
measured after T = 48 hours to ensure that the nanoparticles are able to diffuse far away
from the vasculature. The number of internalized nanoparticles estimated to theoretically
induce cytotoxicity in a single cell was calculated to be 600 using the equation
, where NA is the Avogadro constant. Setting NP0 = 20 NPc in Eq. 1
corresponds to a local concentration of 10uM in all 20 cell regions of the scenario, which is
the IC90 of doxorubicin. An injected dose ID = 3.3 mg/kg of doxorubicin is computed to be
sufficient to kill all 20 cells if the nanoparticles distribute uniformly along the linear section
of tumor in the model. However, to increase the likelihood that sufficient numbers of
nanoparticles reach all cells, we administer a dose of 33 mg/kg, 10 times in excess of the
theoretically sufficient dose. This corresponds to an initial nanoparticle population in the
tumor model of NP0 = 1.2044 · 105, corresponding to a maximum concentration of 200 nM
(for the nanoparticles) or 2 mM of doxorubicin in a cell region. As a reference, the typical
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injected dose for liposomal doxorubicin in humans ranges from 20 mg/m2 to 70 mg/m2 [39],
corresponding to a mouse equivalent range between 6.6 mg/kg and 25 mg/kg [40]. Doses up
to 55 mg/kg have been shown to cause reversible weight loss in mice [41].
Fig. 2A shows the number of cells that are dead after 48 hours of treatment as a function of
D and KD, simulated using both the stochastic model and the deterministic model. Note that
the identical results from both models validate the use of the deterministic model for
prediction and optimization. Based on experimental work by Hong et al. [6, 25] and Thurber
et al. [6], we maintained the dissociation and internalization rate constants at kd = 10−4 s−1,
ki = 10−5 s−1 while varying ka in the range [103, 109] M−1s−1. These are the parameter
ranges used throughout the paper, unless stated otherwise. Fig. 2B shows the penetration
profiles of several nanoparticle formulations. As further validation, previous models by
Thurber et al. [6] for antibody penetration showed that treatments with D = 3 · 10−7 cm2/s
and KD = 8 nM were able to penetrate a depth of at least 200 μm into tumor tissue while
antibodies with KD = 30 pM were not, which is consistent with findings presented here. The
results show that most of the nanoparticle formulations considered are not capable of killing
all 20 cells in the model. Nanoparticles with a high binding affinity (Fig. 2B(a),(c)),
regardless of their speed, accumulate only in cells near the vasculature, and slow
nanoparticles (Fig. 2B(c,d)) fail to accumulate at lethal levels in cells farthest from the
vasculature. Fast nanoparticles with a low binding affinity are able to accumulate at lethal
levels in all cells (Fig. 2B(b)).
However, lowering the affinity beyond the range explored here could result in nanoparticles
that are unable to accumulate at lethal levels in tumor cells. Simulations show this to be true
for nanoparticles with dissociations constants in the micro-molar range. For the remaining
formulations, a balance between nanoparticle speed and binding affinity is required to treat
cells throughout the entire tumor section. Other studies have suggested that multivalency
mostly affects the dissociation rate rather than the association rate [42]. In Fig. 2C we show
that maintaining ka =104 M−1s−1 constant and varying kd in the range [10−6,1] s−1 yields
similar results. Overall, many of the targeted nanoparticle formulations in the literature
would result in binding-site barriers in the scenario proposed here (Fig. 2D and Table 1). To
overcome this barrier, nanoparticles would require a reduction in size to produce a higher
diffusion coefficient or a fine-tuning of their binding affinity. For liposomes, size variation
can be achieved by choosing the appropriate extrusion membrane [43]. Reducing the
valency of the targeting ligand or engineering the ligand itself can reduce affinity [25, 44].
For many nanoparticles formulations however, size and affinity manipulations are time-
consuming and detrimental to nanoparticle function [45].
The common solution to overcome binding-site barriers is to increase the injected dose, ID.
Saturating the first cells after extravasation could enable excess nanoparticles to overcome
the barrier and penetrate deeper into the tissue. To test this hypothesis in simulation, we
determined the minimum injected dose needed for each of the 20 cells to accumulate
sufficient internalized nanoparticles to kill an individual cell, NPc, for each parameter set
(KD, D). Using branch and bound optimization, we computed this minimum injected dose as
the value in the range [IDmin, IDmax] = [0, 33000] mg/kg that maximizes the following
function:
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Cell death was predicted from the deterministic model, which was initialized with the free
nanoparticle population NP0 that corresponds to the computed ID according to Eq. 1. As
shown in Fig. 2E, 400-fold increases in dose from 33 mg/kg would be required to overcome
binding-site barriers for several nanoparticle formulations, leading to systemic toxicity for
the treated mice [41].
3.2 Time-Dependent Binding
Rather than increase the injected dose or fine-tune nanoparticle formulations, we propose a
generalizable solution to achieve targeted deep tissue penetration with a broad range of
nanoparticle designs. We consider a strategy in which nanoparticles are initially prevented
from binding while diffusing through tumor tissue. The nanoparticle binding functionality is
then restored as a function of time or an external human-operated trigger such as light, heat,
magnetic fields, or injected chemicals (Fig. 3A) [46]. In the simplest form of this
implementation, nanoparticles would be prevented from binding for a duration Tdelay before
entirely regaining their original binding capabilities. This scenario is modeled by setting the
association rate constant to zero until time Tdelay and to ka thereafter according to a step
function. For each parameter set (KD, D), we determined the minimum values of Tdelay that
lead to the accumulation of a lethal dose of internalized nanoparticles in each cell. Using
line-search optimization, we computed the minimum Tdelay as the value in the range [0,
Tmax] = [0, 48] h that maximizes the following function:
The minimum Tdelay values that lead to the death of all target cells for each parameter set
(KD, D) are given in Fig. 3B. Fast-diffusing nanoparticles with D = 10−6, 10−7, 10−8 cm2/s
can unveil their binding-moieties as early as Tdelay = 3h00, 3h20, 4h55 after injection to
result in full tissue penetration and target cell death. Slower-diffusing nanoparticles with D =
10−9 cm2/s should wait at least 17h15 as shown in Fig. 3C. A single binding delay of 17h15
therefore has the potential to enable all nanoparticle formulations to overcome binding-site
barriers in our simulated scenario without increasing the injected dose. While most
nanoparticle formulations are retained in the tumor environment due to the enhanced
permeability and retention effect [4, 43], small nanoparticles that are prevented from binding
for too long risk diffusing to the rim of the tumor where the pressure difference between the
tumor and the surrounding tissue will irreversibly drive them out of the tumor [5, 8, 47]. As
a reference, it would take the fastest-diffusing nanoparticles in our model approximately 34
hours to diffuse from the center of the simulated tumor to its rim. If fast tissue clearance is a
concern, bioengineers can implement two binding delay regimes of 4h55 for fast
nanoparticles (D = 10−6, 10−7, 10−8 cm2/s) and 17h15 for slow nanoparticles. Another
concern is non-specific uptake of veiled nanoparticles by macrophages present in the tumor
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environment that could prevent their diffusion deep into the tissue. Based on research by
Thurber et al. [48], we estimate the rate of non-specific cellular uptake by macrophages to
be slow relative to diffusion, even for the smallest diffusion coefficient of 10−9 cm2/s
considered here.
The representative scenario used to design these guidelines was chosen to be challenging.
By relaxing the different parameters of the scenario, we show that the delayed binding
strategy can directly be generalized to a large variety of tumor environments without
modification. In particular, we consider scenarios where the cell receptors are not recycled,
the number of cell receptors is reduced (R = 105), the PID of nanoparticles reaching the
tumor is increased (PID = 10%), nanoparticles accumulate immediately in the tumor section
(Tc = 0), and nanoparticles are loaded with lower amounts of drug (E = 103). The number of
cells killed for each parameter set (KD, D), as predicted by the deterministic model with no
binding delay and ID = 33 mg/kg, is plotted in Fig. 3D. The figure shows that while these
scenarios should intuitively reduce the prevalence of binding-site barriers, the majority of
nanoparticle formulations still result in poor tissue penetration and cellular accumulation.
Fig. 3E shows that delaying the binding by 17h15, as suggested by our guidelines, results in
complete cell death in all scenarios considered. We further tested the impact of slow drug
release by nanoparticles implementing the delayed binding strategy. Results show that
nanoparticles that are only able to deliver 30% of their cargo within 48 hours are still able to
kill all cells for formulations with fast diffusion (D = 10−6, 10−7, 10−8 cm2/s) while killing
half of the cells when the diffusion is slow (D = 10−9 cm2/s).
3.3 Space-Dependent Binding
Beyond targeted deep tissue penetration, we aim to ultimately control the spatial distribution
of nanoparticles in tissue. In our simulations, more nanoparticles internalized in cells located
near the vasculature than in cells present at deeper sites in the tissue. Inverting this gradient,
i.e., achieving low amounts of internalized nanoparticles near the vasculature and high
amounts deep in the tissue, could be beneficial to deliver large doses of drugs deep into
tumors. To produce this inverted gradient, the unveiling of binding-moieties should rely on
local, spatially-dependent signals in the environment rather than on a global external signal
(time- or human-triggered). In the simplest case, nanoparticles can react to natural gradients
in the tumor environment based on pH or enzymatic activity [7, 49–55]. To account for the
impact of the environment, we introduce a new species in our reaction-diffusion system
called unveilers, represented with the symbol U, and a species of veiled freely diffusing
nanoparticles denoted by NPV. Unveilers are abstractions for elements that could be used as
triggers for unveiling binding moieties. As an example, we consider a scenario where the
population level of unveilers, U(x,t), is initially distributed in the tumor model according to
U(x,0) = cx, where c is an arbitrary constant and x is the distance from the vessel. We then
add a reaction to the network described in Eq. 2 in which a veiled nanoparticle NPV that
encounters an unveiler U will become an unveiled nanoparticle NPF at rate constant ku. Fig.
4 shows a tissue penetration profile computed by the stochastic simulator for the original
test-case scenario with c = 5· 107, D = 10−8 cm2/s, KD = 0.01 nM, ku = 6· 102 M−1s−1, and
ID = 33 mg/kg. Without unveilers, these parameter values result in a binding-site barrier, as
shown in Fig. 2A. As illustrated in Fig. 4, the unveilers cause nanoparticles to internalize
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most in cells located far from the vasculature, producing an inverted internalization gradient
and killing cells deep in the tumor tissue. In the future, a better understanding of the tumor
environment and the binding kinetics of nanoparticles could lead to increased control over
nanoparticle distribution in tumor tissue. This level of control could be useful to create
nanoparticle-based beacon systems or maps that point out areas of interest in the body or
produce communication signals that can be sensed by other nanoparticles [56].
4. Discussion
Using computational frameworks, we are able to provide generalizable guidelines for the
design of novel targeted nanoparticles that can accumulate in cells located deep in tumors.
Building on these guidelines, the next step is to engineer nanoparticles in reality with the
identified features. Bioengineers have already designed and constructed a number of
nanoparticles that are able to shield targeting moieties, or non-specific cellular uptake
mechanisms mediated by charge or cell penetrating peptides (CPP), as a function of protease
activity or pH levels in tumor environments [8, 49]. Interestingly, most of these
nanoparticles were intended to increase the macroscopic accumulation of nanoparticles in
tumors as opposed to healthy tissue [50, 52, 57–61]. Results reported here suggest that
repurposing these shielding mechanisms could result in a generalizable strategy to improve
micro-scale distributions of nanoparticles within the tumor tissue itself. In particular,
nanoparticles engineered by Harris et al. [52] are able to unveil most targeting moieties in
tumor environments within 24 hours based on enzymatic activity and have shown increased
tumor penetration as a result. In a similar fashion, MMP-activatable cell-penetrating
peptides were shown to penetrate well beyond the blood vessels from which they extravasate
[57, 59]. Layer-by-layer nanoparticles described by Poon et al. [50] are able to unveil a
positively charged nanoparticle surface as a function of pH within the tumor environment,
with 50% of the unveiling happening within 3 to 4 hours in the tumor. pH titratable iron
oxide nanoparticles produced by Crayton et al. are able to accumulate in acidic tumor
microenvironments by changing from neutral to positively charged [60]. Romberg et al.
review the different mechanisms that can be used to shed nanoparticle PEG coatings to
improve drug release and cellular uptake while increasing circulation time [61]. Lee et al.
propose a remote optical switch for the spatial and temporal control of nanoparticle
functionalities [62]. Finally, work by Partlow et al. [63] suggests that lipid raft transport with
membrane targeted nanoparticles could enable targeted delivery of lipophilic substances
without the need for entire nanoparticle internalization, thereby improving the ability of
nanoparticles to penetrate deep in tissue. Overall, these advances in nanoparticle engineering
are strong indications that the design guidelines identified here can be translated to working
systems in reality.
5. Conclusions
Nanoparticles targeted to cancer cells are designed to specifically deliver treatment cargos.
While they are able to passively accumulate in tumor tissue through the enhanced
permeability and retention effect [4], targeted nanoparticles often internalize in the first cells
they encounter after extravasation. Indeed, the diffusive nature of certain tumor
environments and the strong binding affinity of many nanoparticles in the literature result in
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the development of binding-site barriers. Overcoming these barriers would require large
doses of nanoparticles that could lead to systemic toxicity [41]. Instead, we propose novel
generalizable guidelines that enable a non-toxic dose of nanoparticles to achieve full tissue
penetration and accumulate at effective levels in all target cells. The strategy is to delay
binding until after nanoparticles have had time to diffuse deep into the tissue. By applying
optimization techniques to simulated models of nanoparticle distributions in tumor tissue,
we show that the time delay after which nanoparticle binding should be initiated is
generalizable to a large variety of nanoparticle formulations and tumor scenarios. Recent
advances in nanoparticle shielding technology provide evidence that such a strategy could
be implemented in reality. In the future, we aim to further control the spatial distribution of
nanoparticles in tissue based on local signals in the environment.
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Highlights
• Binding and diffusion affect the penetration of targeted nanoparticles in tumors.
• Simulations show many nanoparticle formulations accumulate in cells near
vessels.
• Shielding prevents nanoparticles from binding until they diffuse deep in tissue.
• Shielding strategy is generalizable to many nanoparticles and tumor scenarios.
• Time or space-dependent binding enables engineered nanoparticle tissue
distributions.
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Fig. 1. Model used to simulate tissue penetration and cellular accumulation of targeted
nanoparticles
A) Targeted nanoparticles are at risk of accumulating mostly in cells close to the
vasculature, leading to binding-site barriers. B) Parameters used to determine the number of
injected nanoparticles that will reach the simulated tumor section. The tissue section model
represents a challenging scenario in which nanoparticles leaving vessels near the necrotic
core of the tumor need to penetrate deep into tumor tissue. C) Reaction-diffusion model used
to simulate the diffusion, binding kinetics, and cellular internalization of targeted
nanoparticles in tumor tissue. Free nanoparticles diffuse throughout the tissue with diffusion
coefficient D. The species in the reaction network are defined as NPF, free nanoparticles;
NPI, internalized nanoparticles; R, receptors; and C, nanoparticle-receptor complexes. ka
and kd are the association and dissociation rate constants and ki is the internalization rate
constant.
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Fig. 2. Identification of binding-site barriers
A) Number of cells killed depending on the nanoparticle formulation (i.e., diffusion
coefficient D and dissociation constant KD = kd/ka) with kd fixed and ka varying. Complete
tissue penetration is assumed when each of the 20 cells in the model internalizes the number
of nanoparticles required to kill one cell (estimated lethal cell dose), which for this scenario
is over 600 nanoparticles. Results obtained using the deterministic model are validated using
a stochastic simulator. B) Tissue penetration profiles determined using a stochastic simulator
for four combinations of the diffusion coefficients and dissociation constants labeled in Fig.
2A. C) Number of cells killed depending on the nanoparticle formulation with ka fixed and
kd varying (KD = kd/ka). D) Representative nanoparticle formulations identified in the
literature (Table 1). Diffusion coefficients were calculated based on nanoparticle radii and
viscosities ranging from values for water to values for tumor tissue rich in collagen fiber [4].
Many formulations in the literature would perform poorly in our test scenario due to
binding-site barriers, which occur for each parameter set (KD, D) below the dashed line. E)
Minimum injected dose of chemotherapy required to theoretically kill all cells in the
simulated scenario for each nanoparticle formulation. Resulting high doses could cause
systemic toxicity in mice [41].
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Fig. 3. Time-dependent binding strategy for targeted deep tissue penetration
A) The delayed binding strategy allows nanoparticles to diffuse deep into the tissue before
unveiling their targeting moieties as a function of time or an external trigger. B) Minimum
binding delays leading to the death of all target cells for each nanoparticle formulation. For
each diffusion rate, we note the minimum Tdelay value that would result in death of all target
cells across each dissociaiton constant (dashed lines). C) Stochastic simulation of the
delayed binding strategy for a nanoparticle formulation with the Tdelay value indicated in
Fig. 3B. The delay in binding can clearly be seen by the lack of internalization during the
first hours of the simulation. A lethal dose in a cell is reached when the cell accumulates
over 600 nanoparticles. D) Impact of the scenario on the prevalence of binding-site barriers,
as predicted by the deterministic model. Each simulated scenario uses an injected dose of 33
mg/kg, does not implement a binding delay, and varies one of the following parameters:
nanoparticle circulation time, receptor recycling, receptor expression, nanoparticle
accumulation in the tumor, and drug loading. Binding-site barriers arise in all scenarios. E)
Delaying binding by 17h15 for all nanoparticle formulations leads to death of all target cells
in all scenarios without changing the injected dose of 33 mg/kg, thereby demonstrating the
generalization of our guidelines to a large number of tumor environments.
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Fig. 4. Space-dependent binding strategy for targeted deep tissue penetration
Nanoparticles are engineered to unshield targeting moieties as a function of their
environment. The stochastic simulator was used to obtain a tissue penetration profile for
nanoparticles engineered to accumulate most in cells far away from the vasculature; such
inverted internalization gradients could help deliver drugs deep into tumors.
Hauert et al. Page 19
Nano Today. Author manuscript; available in PMC 2014 July 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Hauert et al. Page 20
Table 1
Nanoparticle radii and dissociation constants reported in the literature.
# r [nm] KD [nM] Scenario Ref
1 38 2.84 – 9.08 Iron oxide nanoparticles targeted to FKBP12 [26]
2 4 0.03 – 2.00 Dendrimer-based nanodevices targeted to folate receptors [25]
3 81, 87 0.03, 0.23 Gold nanoparticles targeted to human transferrin [27]
4 94.2, 102.2, 128.9, 117.4 1.98, 2.59, 0.59, 0.38 Liposomal nanoparticles targeted to RGD [28]
5 120 0.18 – 11.76 Liposomes targeted to EGFR [29]
6 2, 10, 25, 40, 50, 70 0.09, 0.005, 0.0009, 0.0004, 0.0003,
0.00015
Gold nanoparticles targeted to ErbB2 [30]
7 90 0.017, 0.04, 0.092, 0.15, 0.2, 3.1, 3.3 Patchy micelles targeted to folate receptors [31]
8 20, 100, 200, 500 142, 3.83, 0.097, 0.026 Polystyrene nanoparticles targeted to endothelial cells [32]
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Table 2
Parameter values for the simulation test-case scenario.
S largest cell dimension 10 μm
NR number of receptors per cell 106
W animal weight 20 g
ID injected dose of doxorubicin 33 mg/kg
PID percentage of injected dose in tumor 1%
E number of molecules of doxorubicin per particle 104
P IC90 of doxorubicin 10 μM
M molar mass of doxorubicin 543.52 g/mol
VT tumor volume 5 mm × 5 mm × 5 mm
L desired tissue penetration depth 200 μm
T time at which PID is measured 48 hours
TC circulation time of the nanoparticles 24 hours
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